|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||355.478 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Cyprodime is a selective opioid antagonist which blocks the μ-opioid receptor, but without affecting the δ-opioid or κ-opioid receptors. This makes it useful for scientific research as it allows the μ-opioid receptor to be selectively deactivated so that the actions of the δ and κ receptors can be studied separately, in contrast to better known opioid antagonists such as naloxone which block all three opioid receptor subtypes.
- Tianeptine, an atypical, selective MOR full-agonist licensed for major depression since 1989.
- Samidorphan, an opioid antagonist preferring the MOR, which is under development for major depression.
- Schmidhammer H, Burkard WP, Eggstein-Aeppli L, Smith CF (February 1989). "Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist". Journal of Medicinal Chemistry. 32 (2): 418–21. doi:10.1021/jm00122a021. PMID 2536439.
- Márki A, Monory K, Otvös F, Tóth G, Krassnig R, Schmidhammer H, et al. (October 1999). "Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays". European Journal of Pharmacology. 383 (2): 209–14. doi:10.1016/s0014-2999(99)00610-x. PMID 10585536.